Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Tuberc Lung Dis ; 24(8): 820-828, 2020 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-32912387

RESUMEN

ALTHOUGH CURABLE, TB frequently leaves the individual with chronic physical and psycho-social impairment, but these consequences have been largely neglected. The 1st International Post-Tuberculosis Symposium (Stellenbosch, South Africa) was held to discuss priorities and gaps in addressing this issue. A barrier to progress has been the varied terminology and nomenclature, so the Delphi process was used to achieve consensus on definitions. Lack of sufficient evidence hampered definitive recommendations in most domains, including prevention and treatment of post-TB lung disease (PTLD), but the discussions clarified the research needed. A consensus was reached on a toolkit for future PTLD measurement and on PTLD patterns to be considered. The importance of extra-pulmonary consequences and progressive impairment throughout the life-course was identified, including TB recurrence and increased mortality. Patient advocates emphasised the need to address the psychological and social impacts post TB and called for clinical guidance. More generally, there is an urgent need for increased awareness and research into post-TB complications.


Asunto(s)
Tuberculosis , Consenso , Humanos , Pulmón , Sudáfrica , Tuberculosis/diagnóstico , Tuberculosis/tratamiento farmacológico
2.
CPT Pharmacometrics Syst Pharmacol ; 6(8): 552-559, 2017 08.
Artículo en Inglés | MEDLINE | ID: mdl-28575552

RESUMEN

The human species is becoming increasingly obese. Dapsone, which is extensively used across the globe for dermatological disorders, arachnid bites, and for treatment of several bacterial, fungal, and parasitic diseases, could be affected by obesity. We performed a clinical experiment, using optimal design, in volunteers weighing 44-150 kg, to identify the effect of obesity on dapsone pharmacokinetic parameters based on maximum-likelihood solution via the expectation-maximization algorithm. Artificial intelligence-based multivariate adaptive regression splines were used for covariate selection, and identified weight and/or age as predictors of absorption, systemic clearance, and volume of distribution. These relationships occurred only between certain patient weight and age ranges, delimited by multiple hinges and regions of discontinuity, not identified by standard pharmacometric approaches. Older and obese people have lower drug concentrations after standard dosing, but with complex patterns. Given that efficacy is concentration-dependent, optimal dapsone doses need to be personalized for obese patients.


Asunto(s)
Dapsona/farmacocinética , Obesidad/sangre , Adulto , Factores de Edad , Anciano , Peso Corporal , Dapsona/sangre , Cálculo de Dosificación de Drogas , Femenino , Humanos , Masculino , Persona de Mediana Edad , Aprendizaje Automático Supervisado , Adulto Joven
3.
CPT Pharmacometrics Syst Pharmacol ; 5(12): 674-681, 2016 12.
Artículo en Inglés | MEDLINE | ID: mdl-27869362

RESUMEN

Trimethoprim-sulfamethoxazole (TMP-SMX) is one of the most widely drugs on earth. The World Health Organization recommends it as an essential basic drug for all healthcare systems. Dosing is inconsistently based on weight, assuming linear relationships. Given that obesity is now a global "pandemic" it is vital that we evaluate the effect of obesity on trimethoprim-sulfamethoxazole concentrations. We conducted a prospective clinical experiment based on optimized design strategies and artificial intelligence algorithms and found that weight and body mass index (BMI) had a profound effect on drug clearance and volume of distribution, and followed nonlinear fractal geometry-based relationships. The findings were confirmed by demonstrating decreased TMP-SMX peak and area under the concentration-time curves in overweight patients based on standard regression statistics. The nonlinear relationships can now be used to identify new TMP-SMX doses in overweight and obese patients for each of the infections caused by the >60 pathogens for which the drug is indicated.


Asunto(s)
Antibacterianos/farmacocinética , Obesidad/complicaciones , Sobrepeso/complicaciones , Combinación Trimetoprim y Sulfametoxazol/farmacocinética , Adulto , Anciano , Antibacterianos/administración & dosificación , Inteligencia Artificial , Peso Corporal , Cálculo de Dosificación de Drogas , Femenino , Fractales , Humanos , Masculino , Tasa de Depuración Metabólica , Persona de Mediana Edad , Estudios Prospectivos , Combinación Trimetoprim y Sulfametoxazol/administración & dosificación , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA